NewzA new analysis suggests that projected savings from a highly touted Trump administration plan to lower Medicare drug costs may be drastically reduced by as much as 80 percent.
The potential reduction in savings stems from secretive deals cut between the administration and more than two dozen pharmaceutical companies. These confidential agreements reportedly undermine the framework of the administration's proposed 'most-favored nation' pricing policy for prescription drugs.
In-depth summary · AI, neutral